Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer
NCT ID: NCT02136342
Last Updated: 2014-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
INTERVENTIONAL
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
NCT02245204
Study of ZG0895.HCl in Patients With Advanced Solid Tumors
NCT05877664
SJG-136 in Treating Patients With Advanced Solid Tumors
NCT00103220
A Study of CSPCHA131 in Patients With Advanced Solid Tumor
NCT04325711
Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors
NCT06932094
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
chlorogenic acid
chlorogenic acid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
chlorogenic acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Karnofsky performance status no less than 70
* adequated organ function
* informed consent
Exclusion Criteria
* persistent toxicities from previous treatment (no less than grade 2)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
INDUSTRY
Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shi Yuankai
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuankai Shi, Dr.
Role: PRINCIPAL_INVESTIGATOR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LYS-I-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.